The role of Sandostatin in acromegaly.
Long-acting somatostatin analogues are extensively used for the treatment of acromegalic patients who have not been cured by surgery or for whom surgery is contraindicated or hazardous. Such an analogue, Sandostatin, has been approved for this indication in various countries and to date an overall review is feasible. From the literature and our experience, clinical response of acromegaly is attained in 60% to 70%, with mainly a reduction in headaches, arthralgias, and acral growth. Hormonal response, evaluated on plasma growth hormone (GH) levels, is observed in more than 80% of the patients. In 36% to 45% of the patients, plasma GH levels are reduced to near-normal values, and in 50% of the patients, the percentage of reduction is greater than 50% of pretreatment values. The major source of concern is the occurrence of gallstones during the treatment; its frequency is evaluated differently. From the largest well-documented series, we retain a percentage of 12.5% of newly occurring cholelithiasis and in most cases they remain asymptomatic. Tumor shrinkage is minor in most cases.
Sassolas
G
G
Centre de Médecine Nucléaire, Hôpital Neuro-Cardiologique, Lyon, France.
D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism; D002769:Cholelithiasis / Q000139:chemically induced; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide